Your browser doesn't support javascript.
loading
Massively parallel, computationally guided design of a proenzyme.
Yachnin, Brahm J; Azouz, Laura R; White, Ralph E; Minetti, Conceição A S A; Remeta, David P; Tan, Victor M; Drake, Justin M; Khare, Sagar D.
Affiliation
  • Yachnin BJ; Department of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
  • Azouz LR; Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
  • White RE; Department of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
  • Minetti CASA; Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
  • Remeta DP; Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455.
  • Tan VM; Department of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
  • Drake JM; Department of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
  • Khare SD; Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
Proc Natl Acad Sci U S A ; 119(15): e2116097119, 2022 04 12.
Article in En | MEDLINE | ID: mdl-35377786
ABSTRACT
Confining the activity of a designed protein to a specific microenvironment would have broad-ranging applications, such as enabling cell type-specific therapeutic action by enzymes while avoiding off-target effects. While many natural enzymes are synthesized as inactive zymogens that can be activated by proteolysis, it has been challenging to redesign any chosen enzyme to be similarly stimulus responsive. Here, we develop a massively parallel computational design, screening, and next-generation sequencing-based approach for proenzyme design. For a model system, we employ carboxypeptidase G2 (CPG2), a clinically approved enzyme that has applications in both the treatment of cancer and controlling drug toxicity. Detailed kinetic characterization of the most effectively designed variants shows that they are inhibited by ∼80% compared to the unmodified protein, and their activity is fully restored following incubation with site-specific proteases. Introducing disulfide bonds between the pro- and catalytic domains based on the design models increases the degree of inhibition to 98% but decreases the degree of restoration of activity by proteolysis. A selected disulfide-containing proenzyme exhibits significantly lower activity relative to the fully activated enzyme when evaluated in cell culture. Structural and thermodynamic characterization provides detailed insights into the prodomain binding and inhibition mechanisms. The described methodology is general and could enable the design of a variety of proproteins with precise spatial regulation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gamma-Glutamyl Hydrolase / Drug Design / Protein Engineering / Computer-Aided Design / Enzyme Precursors Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gamma-Glutamyl Hydrolase / Drug Design / Protein Engineering / Computer-Aided Design / Enzyme Precursors Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Type: Article